Navigation Links
Telik Announces Third Quarter 2012 Financial Results
Date:11/9/2012

PALO ALTO, Calif., Nov. 9, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.9 million, or $0.78 per share, for the third quarter ended September 30, 2012, compared with a net loss of $2.8 million, or $1.58 per share (adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012), for the comparable period in 2011.

For the quarter ended September 30, 2012, total operating costs and expenses were $1.9 million, compared with $2.9 million in the third quarter of 2011. Operating expenses in the 2012 third quarter included stock-based compensation expense of approximately $0.1 million. Operating expenses were approximately 34% lower in the third quarter of 2012 compared with the same period in 2011, primarily due to lower headcount, corporate and stock-based compensation expenses.

For the nine months ended September 30, 2012, Telik reported a net loss of $6.2 million, or $3.07 per share, compared with a net loss of $9.5 million, or $5.30 per share, for the same period in 2011.  Total operating expenses for the first nine months of 2012 were $6.2 million, compared with $9.6 million for the same period in 2011. Operating expenses in the first nine months of 2012 included approximately $0.6 million in stock-based compensation expense. The reduction in operating expenses of approximately 35% in the first nine months of 2012 compared with the same period in 2011 was primarily due to lower headcount, reduced clinical trial expenses, and lower corporate and stock-based compensation expenses.

At September 30, 2012, Telik had $6.6 million in cash, cash equivalents and investments including restricted investments, compared to $11.7 million at December 31, 2011. In order to meet its current cash requirements beyond the first quarter of 2013, the company will have to raise additional funds through corporate partnering or equity financings. Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the near future.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2012201120122011Operating costs and expenses:Research and development 

$
867$
,305$
2,788$
4,464General and administrative 

1,0111,5503,4235,090Total operating costs and expenses

1,8782,8556,2119,554Loss from operations

(1,878)(2,855)(6,211)(9,554)Interest and other income (expense), net

27631Net loss

$
(1,876)$
(2,848)$
(6,205)$
(9,523)Basic and diluted net loss per share*

$
(0.78)$
(1.58)$
(3.07)$
(5.30)Weighted average shares used to calculate basic and diluted net loss per share*

2,3951,7992,0211,796* Adjusted for the 1-for-30 reverse stock splitSelected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20122011Cash, cash equivalents, investments and restricted investments

$
,642$
,700Total assets

7,44512,412Stockholders' equity

4,6278,299
'/>"/>

SOURCE Telik, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
3. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
4. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
5. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 First Quarter
7. Array BioPharma Announces Proposed Public Offering Of Common Stock
8. Allscripts Announces Third Quarter 2012 Results
9. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
10. Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... MEMPHIS, Tenn. , July 31, 2017 Three Tru-D ... in Yongsan, South Korea . Tru-D, short for "Total ... patient and operating rooms after an environmental services (ES) professional cleans the ... ... "Although ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
Breaking Medicine Technology:
(Date:8/18/2017)... VA (PRWEB) , ... August 18, 2017 , ... ... asset protection services and financial consultations to communities throughout the greater DC region, ... K9 with the goal of rescuing local animals and training them to be ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM ... that serves communities throughout southern Florida, is working to support the Take Stock ... children from low income families. , The Take Stock In Children Foundation (TSC) ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a ... Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide support to ... early June of this year, Christina and her children returned from out of town ...
(Date:8/18/2017)... ... ... and Overseer at The House of Yahweh in Abilene, Texas, has released a new publication ... mother of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared to ... this historical woman. , “The world bows, kisses the feet of, cries out to ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... and call tracking and monitoring solutions, announced today the launch of a redesigned ... a modern navigation and aesthetic, fully responsive design, and an enhanced search directory ...
Breaking Medicine News(10 mins):